Krzysztof Matlak

Krzysztof Matlak

Auto-generated profile, based on publicly available information

Krzysztof Matlak

Department of Cardiac Surgery, Medical University of Bialystok, Bialystok, Poland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2015 in Genome Medicine
Verified
Journal Article
Open access
PDF file
AMAgata Maciejak-Jastrzębska
Agata Maciejak-Jastrzębska
MKMarek Kiliszek
Marek Kiliszek
MMMarcin Michalak
Marcin Michalak
DTDorota Tulacz
Dorota Tulacz
GOGrzegorz Opolski
Grzegorz Opolski
BBBeata Burzyńska
Beata Burzyńska
Background: Heart failure (HF) is the most common cause of morbidity and mortality in developed countries. Here, we identify biologically relevant transcripts that are significantly altered in the early phase of myocardial infarction and are associated with the development of post-myocardial infarction HF. Methods: We collected peripheral blood samples from patients with ST-segment elevation myocardial infarction (STEMI): n = 111 and n = 41 patients from the study and validation groups, respectively. Control groups comprised patients with a stable coronary artery disease and without a history of myocardial infarction. Based on plasma NT-proBNP level and left ventricular ejection fraction parameters the STEMI patients were divided into HF and non-HF groups. Microarrays were used to analyze mRNA levels in peripheral blood mononuclear cells (PBMCs) isolated from the study group at four time points and control group. Microarray results were validated by RT-qPCR using whole blood RNA from the validation group. Results: Samples from the first three time points (admission, discharge, and 1 month after AMI) were compared with the samples from the same patients collected 6 months after AMI (stable phase) and with the control group. The greatest differences in transcriptional profiles were observed on admission and they gradually stabilized during the follow-up. We have also identified a set of genes the expression of which on the first day of STEMI differed significantly between patients who developed HF after 6 months of observation and those who did not. RNASE1, FMN1, and JDP2 were selected for further analysis and their early up-regulation was confirmed in HF patients from both the study and validation groups. Significant correlations were found between expression levels of these biomarkers and clinical parameters. The receiver operating characteristic (ROC) curves indicated a good prognostic value of the genes chosen. Conclusions: This study demonstrates an altered gene expression profile in PBMCs during acute myocardial infarction and through the follow-up. The identified gene expression changes at the early phase of STEMI that differentiated the patients who developed HF from those who did not could serve as a convenient tool contributing to the prognosis of heart failure.

29 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAgata Maciejak-Jastrzębska
Agata Maciejak-Jastrzębska
EKEdyta Kostarska-Srokosz
Edyta Kostarska-Srokosz
WGWlodzimierz Gierlak
Wlodzimierz Gierlak
MDMiroslaw Dluzniewski
Miroslaw Dluzniewski
MKMarek Kuch
Marek Kuch
BBBeata Burzyńska
Beata Burzyńska
Left ventricular (LV) dysfunction after acute myocardial infarction (AMI) is associated with an increased risk of heart failure (HF) development. Diverse microRNAs (miRNAs) have been shown to appear in the bloodstream following various cardiovascular events. The aim of this study was to identify prognostic miRNAs associated with LV dysfunction following AMI. Patients were divided into subgroups comprising patients who developed or not LV dysfunction within six months of the infarction. miRNA profiles were determined in plasma and serum samples of the patients on the first day of AMI. Levels of 14 plasma miRNAs and 16 serum miRNAs were significantly different in samples from AMI patients who later developed LV dysfunction compared to those who did not. Two miRNAs were up-regulated in both types of material. Validation in an independent group of patients, using droplet digital PCR (ddPCR) confirmed that miR-30a-5p was significantly elevated on admission in those patients who developed LV dysfunction and HF symptoms six months after AMI. A bioinformatics analysis indicated that miR-30a-5p may regulate genes involved in cardiovascular pathogenesis. This study demonstrates, for the first time, a prognostic value of circulating miR-30a-5p and its association with LV dysfunction and symptoms of HF after AMI.

1 January 2010 in Journal of Lipid Research
Verified
Journal Article
Open access
MBMarcin Baranowski
Marcin Baranowski
ABAgnieszka Urszula Blachnio-Zabielska
Agnieszka Urszula Blachnio-Zabielska
THTomasz Adam Hirnle
Tomasz Adam Hirnle
DHDorota Harasiuk
Dorota Harasiuk
KMKrzysztof Matlak
Krzysztof Matlak
JGJan Górski
Jan Górski
Data from animal experiments strongly suggest that ceramide is an important mediator of lipotoxicity in the heart and that accumulation of ceramide contributes to cardiomyocyte apoptosis associated with type 2 diabetes and obesity. However, it remains unknown whether a similar relationship is present also in the human heart. Therefore, we aimed to examine whether myocardial apoptosis in obese and type 2 diabetic patients is associated with elevated ceramide level. The study included 11 lean and 26 overweight or moderately obese subjects without (n = 11, OWT) or with (n = 15, T2D-OWT) a history of type 2 diabetes. Samples of the right atrial appendage were obtained from patients at the time of coronary bypass surgery. Compared with lean subjects, the extent of DNA fragmentation (a marker of apoptosis) was significantly higher in the myocardium of OWT patients and increased further in T2D-OWT subjects. However, the content of ceramide and sphingoid bases remained stable. Interestingly, the mRNA level of enzymes involved in synthesis and degradation of ceramide including serine palmitoyltransferase, sphingosine kinase 1, neutral sphingomyelinase, and ceramidases was markedly higher in the myocardium of OWT and T2D-OWT patients compared with lean subjects. Our results indicate that in the human heart, or at least in the atrium, ceramide is not a major factor in cardiomyocyte apoptosis associated with obesity and type 2 diabetes.

27 July 2016 in Molecular Medicine Reports
Verified
Journal Article
Closed access
PDF file
AMAgata Maciejak-Jastrzębska
Agata Maciejak-Jastrzębska
MKMarek Kiliszek
Marek Kiliszek
GOGrzegorz Opolski
Grzegorz Opolski
ASAgnieszka Segiet
Agnieszka Segiet
KMKrzysztof Matlak
Krzysztof Matlak
GMGora Monika
Gora Monika
Acute myocardial infarction (AMI) is a life-threatening episode of coronary artery disease. Recently, circulating myocardial-derived microRNAs (miRNAs) have been reported as potential biomarkers of infarction. The present study aimed to identify differentially expressed miRNAs in patients with ST-segment elevation myocardial infarction that could be potentially dysregulated in response to early myocardial damage. miRNA expression profile analysis was performed using the Serum/Plasma Focus miRNA Polymerase Chain Reaction (PCR) panel of Exiqon A/S (Vedbaek, Denmark) on plasma samples of patients on the first day of AMI (admission) and on samples from the identical patients collected six months following AMI. Selected miRNAs were validated by reverse transcription‑quantitative PCR (RT‑qPCR) using independent patients with AMI and a control group of patients with a stable coronary artery disease. Thirty‑two species of plasma miRNA were differentially expressed (P<0.05) on admission compared with six months following AMI. Subsequent validation in an independent patient group confirmed that miR‑133b and miR‑22‑5p were significantly up‑regulated in the serum of patients with AMI. The receiver operating characteristic (ROC) curve analysis demonstrated a diagnostic utility for miR-22-5p, which has not previously been reported to be associated with AMI. Among the selected miRNAs, miR‑22‑5p represents a novel promising biomarker for the diagnosis of AMI.

23 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JTJustyna Tokarewicz
Justyna Tokarewicz
BJBarbara Jankowiak
Barbara Jankowiak
KKKrystyna Klimaszewska
Krystyna Klimaszewska
MŚMichał Święczkowski
Michał Święczkowski
KMKrzysztof Matlak
Krzysztof Matlak
SDSławomir Dobrzycki
Sławomir Dobrzycki
Introduction: Cardiovascular diseases, particularly myocardial infarction (MI), significantly impact patients’ lives, causing stress and prompting varied responses to illness. Aim and methods: We conducted a narrative review concerning the acceptance of illness and quality of life in post-MI patients. Based on an extensive search of the available literature, this review consolidates current evidence on the proposed topic. Conclusions and implications: While some patients struggle with acceptance and face emotional distress, others who accept their condition are more likely to engage in treatment and lifestyle changes, leading to an improved health-related quality of life (HRQoL). Following an MI, patients often experience depression, anxiety, and stress, complicating their acceptance of the illness. Risk factors, such as hypertension, diabetes, and smoking, play a significant role in influencing HRQoL in post-MI patients. An accurate assessment of HRQoL is crucial for tailoring effective treatments and support strategies to enhance patient outcomes and identify those most at risk of developing post-MI depression or anxiety. Effective physician–patient and nurse–patient communication and support from family might be helpful in recovery. Cardiac rehabilitation improves patients’ outcomes and HRQoL. This review underscores the importance of integrating psychological support with optimal medical care to improve patient prognosis and enhance the HRQoL of individuals recovering from MI. The healthcare system could implement routine psychological assessments for MI patients at admission and discharge to establish a baseline for follow-up. Future research should explore effective psychological interventions, the interplay of CVD risk factors and psychosocial aspects, the emerging role of artificial intelligence in personalized care, and the cost-effectiveness of integrated treatment models.

9 September 2016 in Polish Heart Journal
Verified
Journal Article
Closed access
THTomasz Adam Hirnle
Tomasz Adam Hirnle
ASAdrian Stankiewicz
Adrian Stankiewicz
KMKrzysztof Matlak
Krzysztof Matlak
MFMarek Frank
Marek Frank
RTRobert Trzciński
Robert Trzciński
GHGrzegorz Hirnle
Grzegorz Hirnle
Early mortality in the emergency group was higher, while long-term mortality did not differ among the groups. Postoperative ARF is a critical predictor of mortality in both groups.